Delivery Order SPE2DB22D3011-SPE2DB25FP9QF

Award Date 3/4/25
Potential Completion Date 3/5/25
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $35,884.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award, valued at $20,646.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order to supply PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The award is not associated with a set-aside program and is a firm fixed-price contract scheduled for completion by December 20, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award, valued at $7,251.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of July 31, 2024. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $56,671.51, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of July 9, 2024. The contract is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,096.36 delivery order contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty pharmaceutical product. The contract has a period of performance through October 17, 2024 and utilizes a firm fixed price pricing structure. This award is associated with a larger $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,583.60, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 30, 2025. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $24,339.01 and an ultimate completion date of February 10, 2025. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $12,596.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a critical medical product, with a completion date of May 6, 2022. This is a delivery order contract with a firm fixed price pricing type. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., is a key vendor for federal healthcare...
This federal contract award, valued at $30,965.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm-fixed-price delivery order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of May 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $4,302.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, and is a firm fixed-price delivery order with a completion date of February 27, 2025. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB25FP9QF
    Delivery Order

This federal contract award, valued at $18,772.81, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 5, 2025.

The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to support military healthcare programs. This contract award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established itself as a key vendor for federal healthcare programs, particularly within the DLA Troop Support Medical. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 6/3/25, 10:07 AM